Connect with us
Prague Gaming & TECH Summit 2024

Fintech PR

Scantox acquires QPS Austria’s Neuropharmacology Division

Published

on

scantox-acquires-qps-austria’s-neuropharmacology-division

EJBY, Denmark, Nov. 30, 2023 /PRNewswire/ — Today Scantox, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria GmbH (“QPS Neuro” or “the Company”) ultimately owned by QPS Holdings LLC. QPS Neuro is a leading drug discovery Contract Research Organization (CRO) that specializes in neurodegenerative, rare diseases and mental disorders. The Company is well recognized for its high quality services that are deeply scientifically rooted and has an undisputed track-record of serving a loyal and broad customer base globally. This transformational acquisition will expand Scantox’s value chain coverage and reposition its existing drug discovery platform significantly with unique and market leading central nervous system (CNS) research capabilities.

Founded in 1999, QPS Neuro has a long history of developing expertise within lead-optimization services and efficacy studies. The Company has a 2,700 m2 state-of-the-art facility in Grambach, Austria, and employs more than 80 employees. With on-site availability of validated transgenic and non-transgenic in-vitro and in-vivo models, QPS Neuro addresses multiple targets within the growing CNS area and represents a unique partner for biotech and pharma companies in their drug development process.

“The acquisition of QPS Neuro is meaningfully changing our lead optimization platform and expands the depth and breadth of our discovery services in the CNS and rare disease area. We see a strong fit with the Scantox organization and are deeply impressed with the dedicated management team, its staff and R&D efforts focused on providing an enhanced level of service and scientific excellence to their clients.” says Jeanet Løgsted, CEO of Scantox. 

Manuela Prokesch, Director of QPS Neuro, continues: “This is a unique opportunity for us to join a preclinical market leader, known for their high quality and customer centric approach. We are looking forward to leveraging the synergies across the Scantox organization while continuing to deliver the best customized solutions to our clients.”

QPS Neuro will continue its operations as part of the Scantox group. The combined company will have more than 300 employees across six sites offering discovery models including neuropharmacology research services, regulatory toxicology and CMC/analytical services.

Nicholas Hooge, Partner at Impilo, concludes, “This is a transformational acquisition for Scantox that broadens its service offering and customer reach significantly. We are thrilled to welcome the QPS Neuro team into the Scantox group and see significant growth opportunities for the combined business going forward. As demonstrated by this acquisition, Impilo continues to have strong conviction in the broader pre-clinical market and look forward to continuing working with the enlarged group to further expand its service offering and to strengthen its position globally.”

Sustainability-linked loan

As part of the transaction, Scantox has successfully signed a sustainability-linked loan in collaboration with Nordea and Nykredit. The loan reflects the company’s proactive approach to integrating sustainable practices into its commercial strategy.

Advisors

Lincoln International is serving as corporate finance advisor to Scantox, EY is serving as its financial and tax advisor, L.E.K. Consulting as its commercial advisor and Accura together with DORDA are serving as its legal counsel. Perella Weinberg Partners is serving as financial advisor to QPS Holdings, KPMG is serving as its tax advisor and Ropes & Gray together with Wolf Theiss are serving as its legal counsel.

About Scantox

Scantox is the leading Nordic pre-clinical GLP-accredited CRO, focused on pharmacology and regulatory toxicology, headquartered in Denmark with subsidiaries in Sweden and Denmark. Based on decades of experience, Scantox is a trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, with a world known expertise within the Göttingen minipigs. Scantox’s services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. Founded in 1977, Scantox is today owned by Impilo, the leading Nordic healthcare investment company.

About QPS Neuro

QPS Neuro, the neuropharmacology division of QPS Austria GmbH, is highly experienced and specialized within preclinical CNS services. QPS Neuro has developed its reputation since 1999 as a high quality CRO and a leading specialist within Alzheimer’s, Parkinson’s, ALS, Dementia, Niemann-Pick, Gaucher, Autism, Schizophrenia, Frontotemporal Lobar Degeneration and other neurodegenerative and rare diseases. The Company’s reputation within CNS is further enhanced by its strong capabilities in pre-clinical efficacy studies including in vitro molecular and cellular analysis and proprietary in vivo transgenic mouse and rat models with associated analytics offered to a broad portfolio of customers.

About Impilo

Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in pharmaceuticals, medical technology, healthcare services, and other health-related areas. Impilo strives to increase the value of its investments through long-term active ownership. Impilo has a well-diversified portfolio of investments and has raised c. EUR 1 billion in capital from leading Nordic and international investors since its inception in 2017.

Logo – https://mma.prnewswire.com/media/2288707/Scantox.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/scantox-acquires-qps-austrias-neuropharmacology-division-302002008.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Newmark Group Reports Fourth Quarter and Full Year 2023 Financial Results

Published

on

newmark-group-reports-fourth-quarter-and-full-year-2023-financial-results

Conference Call to Discuss Results Scheduled for 10:00 a.m. ET Today

NEW YORK, Feb. 22, 2024 /PRNewswire/ — Newmark Group, Inc. (Nasdaq: NMRK) (“Newmark” or “the Company”), a leading commercial real estate service provider to large institutional investors, global corporations, and other owners and occupiers, today reported its financial results for the three months and year ended December 31, 2023.

A complete and full-text financial results press release, including information about today’s financial results conference call and Newmark’s dividend declaration, is accessible in the “Media” section at https://nmrk.com. It is also available directly at any of the following web pages:

https://ir.nmrk.com (PDF version of the full press release, PDF of a quarterly results investor presentation, and supplemental Excel financial tables)

https://ir.nmrk.com/investors/news-releases/financial-and-corporate-releases (Links to the PDF version of the full press release, PDF of a quarterly results investor presentation, and to Excel financial tables)

https://nmrk.com/media (PDF version of the full release only)

(Note: If clicking on the above links does not open a new web page, you may need to cut and paste the above URLs into your browser’s address bar.)

Today’s conference call is expected to contain forward-looking statements with respect to the Company’s financial outlook.

ABOUT NEWMARK
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the year ended December 31, 2023, Newmark generated revenues of approximately $2.5 billion. Newmark’s company-owned offices, together with its business partners, operate from approximately 170 offices with 7,400 professionals around the world. To learn more, visit nmrk.com or follow @newmark.

DISCUSSION OF FORWARD-LOOKING STATEMENTS ABOUT NEWMARK
Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company’s business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.

Logo – https://mma.prnewswire.com/media/1057994/Newmark_Group_Inc_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/newmark-group-reports-fourth-quarter-and-full-year-2023-financial-results-302068804.html

Continue Reading

Fintech PR

Singularity Closes $2.2M in Latest Funding Round to Provide Institutions Confidential Access to DeFi

Published

on

singularity-closes-$2.2m-in-latest-funding-round-to-provide-institutions-confidential-access-to-defi

DENVER, Feb. 22, 2024 /PRNewswire/ — Singularity, founded in late 2022, has successfully concluded its second funding round at the end of 2023, with this round led by Gumi Cryptos Capital. The funding will support the development of its protocol, aimed at facilitating compliant access to DeFi as well as ensuring commercial confidentiality for all on-chain activities, with an emphasis on institutional users.

Notable participation from investors such as Nomura’s digital asset subsidiary Laser Digital, Eureka Partners, and previous round investors including Apollo Crypto, Digital Asset Capital Management, and Gandel Invest, underscores top tier institutional and Venture Capital firms’ confidence in Singularity’s vision. With this latest round, Singularity has raised close to US$4 million since its inception.

Singularity is leading the way in developing a KYC/KYB-compliant institutional DeFi access layer, providing access to leading protocols for on-chain institutional participants while prioritizing commercial confidentiality. Users can seamlessly access existing on-chain liquidity and conduct transactions within Singularity, all while benefiting from on-chain anonymity by utilizing advanced zero-knowledge technology.

The initial cohort of institutional users comprises a significant portion of Singularity’s investors, spanning liquid funds, asset managers, and venture capitalists. Singularity stands as one of the first DeFi infrastructure protocols leveraging Noir-based zero-knowledge circuits. Noir is a domain-specific language for SNARK proving systems developed by Aztec Labs. It serves as a universal language for zero-knowledge (ZK) circuits. Users can have confidence in the commercial confidentiality of their on-chain activity protected by state-of-the-art cryptography.

“We look forward to launching in the coming months with our early institutional users. We focused on designing and building in 2023, and, in what was a very difficult year for primary markets, our investors’ commitments validate the institutional need to transact on-chain without information leakages” said Jemma Xu, co-founder of Singularity, “We have an exciting product roadmap ahead with more integrations and multichain deployments. Our immediate focus is on growing our institutional user base.”     

“We are proud to support Singularity in their efforts to advance DeFi accessibility. Singularity addresses a crucial need in the market, providing institutional users with both the compliance and the commercial confidentiality necessary to participate in DeFi. We look forward to partnering with Singularity in this journey,” said Miko Matsumura, Managing Partner at Gumi Cryptos Capital.

“We are excited to support Singularity on its journey to bring private and compliant DeFi accessibility to institutions.” said Jez Mohideen, CEO of Laser Digital.

Users can both leverage the underlying existing on-chain liquidity and transact within the Singularity, obfuscating both wallet addresses and order details. At launch, Singularity will be integrated with some of the major DeFi protocols and will continue to grow its integrations to provide users with a diversity of on-chain strategies.

About Singularity:

Singularity, a protocol developed by PG Foundation, is a compliant institutional DeFi access layer that provides access to popular protocols for institutional on-chain participants with commercial confidentiality. Users will have their wallet addresses obfuscated whilst leveraging existing DeFi liquidity. Singularity uses the state-of-the-art UltraPLONK proof system with zero-knowledge circuits based on Noir.

Contact:

Email: [email protected] 
Website: thesingularity.network
Twitter: https://twitter.com/singularityzk
LinkedIn:
https://www.linkedin.com/company/singularityzk 

View original content:https://www.prnewswire.co.uk/news-releases/singularity-closes-2-2m-in-latest-funding-round-to-provide-institutions-confidential-access-to-defi-302067542.html

Continue Reading

Fintech PR

Kakao Brain Debuts ‘KARA-CXR’, a Web-Based Radiology Report Service Powered by Large-Scale AI

Published

on

kakao-brain-debuts-‘kara-cxr’,-a-web-based-radiology-report-service-powered-by-large-scale-ai

“AI Assistant for Radiologists”

  • Kakao Brain introduced last month a web-based radiology report Research Use Only (RUO) service powered by its large-scale artificial intelligence (AI), “KARA-CXR.”
  • Kakao Brain plans to expand the interactive functions supporting various imaging medical examinations through the advancement of large-scale multi-modal generation AI technology.

SEOUL, South Korea, Feb. 22, 2024 /PRNewswire/ — Kakao Brain has unveiled the research use only (RUO) web-based solution powered by “KARA-CXR” (short for “Kakao Brain AI for Radiology Assistant-CXR”), a large-scale AI algorithm that instantly generates preliminary radiology reports for doctor’s review when chest X-ray images are uploaded onto the web.

Through this user-friendly and seamless solution, medical researchers can experience various functions such as: receiving two types of AI interpretations of chest X-ray images together (a simple report and a detailed full report); ability to upload multiple DICOM files at once and receiving multiple reports simultaneously; and being able to share the AI interpretations within the research group or medical community. It also features compliant security measures that anonymize and protect any personal information contained in DICOM files.

Kakao Brain started developing ‘KARA-CXR’ in 2022, collaborating with 11 leading university hospitals and large medical institutions. Partners include: Ewha Womans University Medical Center (Seoul, Mok-dong), Ajou University Hospital, Soonchunhyang Medical Center (Cheonan, Gumi, Seoul), Chungnam National University Hospital, Chungbuk National University Hospital, Keimyung University Dongsan Medical Center, Inha University Hospital, Dongguk University Ilsan Hospital, among others. ‘KARA-CXR’ has analyzed over 16 million chest X-ray images and readings. KARA-CXR is built on Kakao Brain’s healthcare-specialized large-scale generative AI model, and the research team is preparing to publish the results in influential academic journals.

Kakao Brain is preparing to obtain the European Union certification and seek approval from the US FDA and Korean Ministry of Food and Drug Safety. Kakao Brain is committed to the expansion of AI-powered radiology solution to address the inefficiency in the existing interpretation and reporting process, a shortage of radiologists, and to unburden healthcare professionals from the increasing workload. As an RUO tool, KARA-CXR is currently available for research use only and is not intended to diagnose, treat, cure, or prevent any disease.

Kim Il-doo, CEO of Kakao Brain, stated, “As KARA-CXR was developed using high-quality data and the latest technology involving large-scale learning and generative AI, I hope that it will eventually play a great role in enhancing the workflow for the radiologists, not to mention improving the efficiency of chest x-ray image interpretation.” He also added, “We are planning to go beyond generating AI interpretations of chest X-rays by expanding the algorithms to include interactive functions that support a variety of medical imaging tests, by utilizing the advanced large-scale multi-modal generative AI technology.”

Kakao Brain is a Korea-based global AI technology company. Founded in 2017, Kakao Brain aims to develop AI technology that will change people’s lifestyle and embraces the challenge of asking the ‘Unthinkable Question’ to spark innovation, allowing everyone to live better lives. Kakao Brain has developed numerous innovative AI technologies and services designed to enhance people’s quality of life through continuous technological innovation. These include the large-scale language model KoGPT and the image generation model Karlo. Additionally, Kakao Brain contributes to the development of the AI technology community by releasing ‘Coyo,’ a dataset consisting of approximately 740 million images and text. More information about Kakao Brain can be found on their official website: https://KakaoBrain.com/.

View original content:https://www.prnewswire.co.uk/news-releases/kakao-brain-debuts-kara-cxr-a-web-based-radiology-report-service-powered-by-large-scale-ai-302068283.html

Continue Reading

Trending